Pharmaceutical Commerce - April 2022

Click the title above for a link to open the Pharmaceutical Commerce April 2022 issue in an interactive PDF format.

PC's new editor-in-chief details his thought process on familiarizing himself with a different side of the industry

Ongoing challenges—ranging from the growing complexity of today’s advanced therapy options, to inherent shortcomings in the clinical trial process, to ongoing adherence challenges and more—must be reconciled to ensure both clinical and commercial success throughout cancer care

Biopharma sponsorship of patient-support programs and treatments for rare diseases is growing, but gaps remain

New book attempts to cut through pharma’s patient-centric posturing and start a conversation about real, transformational change

Not quite specialty, not quite retail: Cost-effective access and support strategies for a growing, yet underserved, treatment market

The patient-first, pharmacy-first hub model optimizes outcomes and improves care journey for patients with rare disease

Disruption is the order of the day to create a more individual-centric hub experience from the patient’s point of view

A conversation with Ian Riches, head of patient solutions for Europe, Ashfield Engage

The need for supporting services in copay accumulator and best price areas

Creating positive experiences and other patient-focused strategies for sponsors to consider when planning and executing cancer studies

Company strives to provide essential medicines that are in low supply

It's time to include hubs in the patient treatment journey

Taking advantage of new advances in tech-driven engagement to boost patient support and adherence